26650-79-3

Basic information

• Product Name: 1,3,5-Triazine, 2,4-dichloro-6-(phenylmethyl)-
• CAS NO: 26650-79-3
• Molecular Formula: C10H7Cl2N3
• Molecular Weight: 240.092
• Mol File: 26650-79-3.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 1,3,5-Triazine, 2,4-dichloro-6-(phenylmethyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: 1,3,5-Triazine, 2,4-dichloro-6-(phenylmethyl)-(26650-79-3)
• EPA Substance Registry System: 1,3,5-Triazine, 2,4-dichloro-6-(phenylmethyl)-(26650-79-3)

Safety Data

• Hazardous Substances Data: 26650-79-3(Hazardous Substances Data)

Usage

Structure

A derivative of the heterocyclic compound 1,3,5-triazine with a 2,4-dichloro-6-(phenylmethyl) group attached to the triazine ring.

Chemical reactivity

The addition of the 2,4-dichloro-6-(phenylmethyl) group to the triazine ring provides specific chemical reactivity, making it useful in various chemical reactions and applications.

Applications

May be used as an intermediate in the synthesis of pharmaceuticals, agrochemicals, and other organic compounds due to its unique chemical structure and reactivity.

Potential medicinal and biological activities

The compound is a subject of interest in pharmaceutical research and development due to its potential medicinal and biological activities.

Upstream product

• 108-77-0 1,3,5-trichloro-2,4,6-triazine 
• 100-39-0 benzyl bromide 

Downstream Products

• 1091629-13-8 C₂₇H₄₇N₇O₂ 
• 1233403-91-2 2-benzyl-4-chloro-6-(morpholin-4-yl)-1,3,5-triazine 

Relevant articles and documents

Identification and Preclinical Evaluation of the Bicyclic Pyrimidine γ-Secretase Modulator BMS-932481

A triazine hit identified from a screen of the BMS compound collection was optimized for potency, in vivo activity, and off-target profile to produce the bicyclic pyrimidine γ-secretase modulator BMS-932481. The compound showed robust reductions of Aβsub

S-TRIAZINE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME

Novel s-triazine compounds are disclosed and represented by the following: formula (Ia). The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, where microbial infection is either a direct cause or a related condition.